Search Results - "Botros, Fady T."

Follow‐up of SARS‐CoV‐2 positive subgroup from the Asymptomatic novel CORonavirus iNFection study by Meyers, Kristin J., Dillman, Brian, Williams, Charles, Jiang, Jianfei, Clifford, Nancy, Miller, Jennifer L., Jones, Meghan E., Goetz, Iris A., Botros, Fady T., Knorr, Jack, Manner, David H., Woodward, Brad

“…A nested longitudinal study within theAsymptomatic novel CORonavirus iNFfection study followed participants with positive nasopharyngeal swab to query for…”
Get full text

Collecting Duct Renin Is Upregulated in Both Kidneys of 2-Kidney, 1-Clip Goldblatt Hypertensive Rats by Prieto-Carrasquero, Minolfa C, Botros, Fady T, Pagan, Javier, Kobori, Hiroyuki, Seth, Dale M, Casarini, Dulce E, Navar, L Gabriel

“…Renin in collecting duct cells is upregulated in chronic angiotensin II–infused rats via angiotensin II type 1 receptors. To determine whether stimulation of…”
Get full text

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial by Tuttle, Katherine R, Lakshmanan, Mark C, Rayner, Brian, Busch, Robert S, Zimmermann, Alan G, Woodward, D Bradley, Botros, Fady T

“…Many antihyperglycaemic drugs, including insulin, are primarily cleared by the kidneys, restricting treatment options for patients with kidney disease…”
Get full text

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program by Jendle, Johan, Grunberger, George, Blevins, Thomas, Giorgino, Francesco, Hietpas, Ryan T., Botros, Fady T.

“…Summary Dulaglutide (DU) is a once weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved for the treatment of type 2 diabetes mellitus (T2DM)…”
Get full text

Tadalafil for the Treatment of Pulmonary Arterial Hypertension by Oudiz, Ronald J., MD, Brundage, Bruce H., MD, Galiè, Nazzareno, MD, Ghofrani, Hossein Ardeschir, MD, Simonneau, Gerald, MD, Botros, Fady T., PhD, Chan, Melanie, MS, Beardsworth, Anthony, MBBS, Barst, Robyn J., MD

“…Objectives The aim of this study was to evaluate the long-term safety and durability of efficacy of tadalafil for pulmonary arterial hypertension. Background…”
Get full text

Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis by Botros, Fady T, Gerstein, Hertzel C, Malik, Raleigh, Nicolay, Claudia, Hoover, Anastasia, Turfanda, Ibrahim, Colhoun, Helen M, Shaw, Jonathan E

“…Dulaglutide (DU) 1.5 mg was associated with improved composite renal outcomes that included new-onset macroalbuminuria in people with type 2 diabetes with…”
Get full text

Bilirubin exerts renoprotective effects in angiotensin II-hypertension by LeBlanc, Ryan M, Navar, L Gabriel, Botros, Fady T

“…Bilirubin is an endogenous antioxidant and is the end product of heme catabolism by heme oxygenase (HO) and biliverdin reductase. Chronic angiotensin II (Ang…”
Get more information

Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7) by Tuttle, Katherine R., Lakshmanan, Mark C., Rayner, Brian, Zimmermann, Alan G., Woodward, Brad, Botros, Fady T.

“…In patients with type 2 dibetes and moderate‐to‐severe chronic kidney disease, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline…”
Get full text

Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials by Tuttle, Katherine R., McKinney, T. Dwight, Davidson, Jaime A., Anglin, Greg, Harper, Kristine D., Botros, Fady T.

“…Dulaglutide is a once‐weekly glucagon‐like peptide‐1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and…”
Get full text

Genetic suppression of HO-1 exacerbates renal damage: reversed by an increase in the antiapoptotic signaling pathway by Olszanecki, Rafal, Rezzani, Rita, Omura, Shinji, Stec, David E, Rodella, Luigi, Botros, Fady T, Goodman, Alvin I, Drummond, George, Abraham, Nader G

“…Apoptosis has been shown to contribute to the development of acute and chronic renal failure. The antiapoptotic action of the heme oxygenase (HO) system may…”
Get more information

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events by Ferdinand, Keith C, Botros, Fady T, Atisso, Charles M, Sager, Philip T

“…Patients with type 2 diabetes (T2D) have a substantial increased risk for cardiovascular (CV) disease and associated mortality than those without diabetes…”
Get full text

Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme by Bergenstal, Richard M., Philis‐Tsimikas, Athena, Wysham, Carol, Carr, Molly C., Bue‐Valleskey, Juliana M., Botros, Fady T., Blevins, Thomas, Rosenstock, Julio

“…Aims Insulin efsitora alfa (efsitora) is a once‐weekly basal insulin. This review describes the study design and rationale of the efsitora phase 3 Once Weekly…”
Get full text

Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes by Wysham, Carol, Guerci, Bruno, D'Alessio, David, Jia, Nan, Botros, Fady T.

“…Dulaglutide glycaemic efficacy has been demonstrated in the AWARD clinical trial programme. The objective of the present analysis was to determine the major…”
Get full text

Renal Heme Oxygenase-1 Induction with Hemin Augments Renal Hemodynamics, Renal Autoregulation, and Excretory Function by Botros, Fady T., Navar, L. Gabriel, Dobrowolski, Leszek

“…Heme oxygenases (HO-1; HO-2) catalyze conversion of heme to free iron, carbon monoxide, and biliverdin/bilirubin. To determine the effects of renal HO-1…”
Get full text

356-OR: Effect of Dulaglutide on Kidney Function–Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial by SHAW, JONATHAN E., BOTROS, FADY T., MALIK, RALEIGH, ATISSO, CHARLES, COLHOUN, HELEN M., GERSTEIN, HERTZEL C.

“…In participants with type 2 diabetes (T2D) in the REWIND trial, dulaglutide (DU) use for median follow-up of 5.4 years was associated with reduced composite…”
Get full text

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial by Franek, Edward, Gerstein, Hertzel C., Riddle, Matthew C., Nicolay, Claudia, Hickey, Ana, Botros, Fady T., Loo, Li Shen

“…Aim To assess cardiovascular, glycaemic, weight and safety outcomes of long‐term treatment with dulaglutide 1.5 mg compared with placebo in patients with a…”
Get full text

Tadalafil for the Treatment of Pulmonary Arterial Hypertension: A Double-Blind 52-Week Uncontrolled Extension Study by OUDIZ, Ronald J, BRUNDAGE, Bruce H, GALIE, Nazzareno, HOSSEIN ARDESCHIR GHOFRANI, SIMONNEAU, Gerald, BOTROS, Fady T, CHAN, Melanie, BEARDSWORTH, Anthony, BARST, Robyn J

“…The aim of this study was to evaluate the long-term safety and durability of efficacy of tadalafil for pulmonary arterial hypertension. Tadalafil is an oral…”
Get full text

Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide by Tuttle, Katherine R, Wilson, Jonathan Matthew, Lin, Yanzhu, Qian, Hui-Rong, Genovese, Federica, Karsdal, Morten Asser, Duffin, Kevin L, Botros, Fady T

“…In the AWARD-7 study in patients with type 2 diabetes and moderate-to-severe chronic kidney disease, once-weekly dulaglutide slowed the decline in estimated…”
Get more information

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial by Gerstein, Hertzel C, Hart, Robert, Colhoun, Helen M, Diaz, Rafael, Lakshmanan, Mark, Botros, Fady T, Probstfield, Jeffrey, Riddle, Matthew C, Rydén, Lars, Atisso, Charles Messan, Dyal, Leanne, Hall, Stephanie, Avezum, Alvaro, Basile, Jan, Conget, Ignacio, Cushman, William C, Hancu, Nicolae, Hanefeld, Markolf, Jansky, Petr, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A, Lopez-Jaramillo, Patricio, Muñoz, Ernesto Germán Cardona, Pogosova, Nana, Raubenheimer, Peter J, Shaw, Jonathan E, Sheu, Wayne H-H, Temelkova-Kurktschiev, Theodora

“…Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide…”
Get full text

A cross‐sectional community‐based observational study of asymptomatic SARS‐CoV‐2 prevalence in the greater Indianapolis area by Meyers, Kristin J., Jones, Meghan E., Goetz, Iris A., Botros, Fady T., Knorr, Jack, Manner, David H., Woodward, Brad

“…The Asymptomatic novel CORonavirus iNfection (ACORN) study was designed to investigate the prevalence of severe acute respiratory syndrome coronavirus 2…”
Get full text